Radiolabeled Monocyte Chemotactic Protein 1 for the Detection of Inflammation in Experimental Atherosclerosis

Chemotactic peptides, such as Monocyte Chemotactic Protein 1 (MCP-1), play a key role in transendothelial migration of mononuclear cells during the development and progression of atherosclerotic disease. Because atherosclerotic plaques that are precursors of acute coronary events harbor abundant macrophage infiltration, we hypothesized that the detection of a high concentration of MCP-1 receptors on inflammatory cells should noninvasively identify vulnerable plaques. Methods: Atherosclerotic lesions were induced by balloon deendothelialization of the abdominal aorta, which was followed by a 0.5% cholesterol diet for 16 wk in 7 New Zealand White rabbits; 5 unmanipulated rabbits, fed normal chow for 16 wk, were used as controls. Radionuclide imaging was performed immediately after intravenous 99mTc-labeled MCP-1 administration and 3 h later. At the end of imaging session, aortas were explanted and submitted for estimation of quantitative MCP-1 uptake (in percentage injected dose per gram, %ID/g) and pathologic characterization. Results: Atherosclerotic lesions were clearly visible in all hyperlipidemic animal γ-imaging. No tracer uptake was seen in the control rabbits. The mean quantitative MCP-1 uptake in atherosclerotic lesions was 4-fold higher than that of the aortic specimens from the control rabbits (0.065 ± 0.005 vs. 0.016 ± 0.006; P < 0.0001). Histology confirmed a strong correlation between MCP-1 uptake and the number of macrophages in American Heart Association type II−IV lesions (r = 0.87, P < 0.0001). Conclusion: Noninvasive radionuclide imaging of inflammation is feasible by MCP-1 in experimentally induced atherosclerosis. It is proposed that detection of the extent of inflammation in advanced atherosclerotic plaques may allow identification of unstable plaques.

[1]  R. Strieter,et al.  Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. , 1989, Biochemical and biophysical research communications.

[2]  M. Waterfield,et al.  The CC Chemokine Monocyte Chemotactic Peptide-1 Activates both the Class I p85/p110 Phosphatidylinositol 3-Kinase and the Class II PI3K-C2α* , 1998, The Journal of Biological Chemistry.

[3]  U. Ikeda,et al.  Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. , 1995, Circulation research.

[4]  R. Virmani,et al.  Targeting of Apoptotic Macrophages and Experimental Atheroma With Radiolabeled Annexin V: A Technique With Potential for Noninvasive Imaging of Vulnerable Plaque , 2003, Circulation.

[5]  E. Butcher.  Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity , 1991, Cell.

[6]  V. Fuster,et al.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. , 2007, Journal of the American College of Cardiology.

[7]  R. Virmani,et al.  Resolution of apoptosis in atherosclerotic plaque by dietary modification and statin therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Y. Kaneda,et al.  Local Overexpression of Monocyte Chemoattractant Protein‐1 at Vessel Wall Induces Infiltration of Macrophages and Formation of Atherosclerotic Lesion: Synergism With Hypercholesterolemia , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[9]  W D Wagner,et al.  A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[10]  M. Isobe,et al.  Imaging of intercellular adhesion molecule-1 induction in rejecting heart: a new scintigraphic approach to detect early allograft rejection. , 1993, Transplantation proceedings.

[11]  A. Roach,et al.  Human vascular smooth muscle cells express receptors for CC chemokines. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[12]  P. Libby,et al.  Inflammation and thrombosis: the clot thickens. , 2001, Circulation.

[13]  B. Rollins.  Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. , 1996, Molecular medicine today.

[14]  A. Sinusas,et al.  Vascular cell adhesion molecule-1-targeted detection of endothelial activation in human microvasculature. , 2004, Transplantation Proceedings.

[15]  A. Freiman,et al.  Association of vascular 18F-FDG uptake with vascular calcification. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  E. Antman,et al.  Association Between Plasma Levels of Monocyte Chemoattractant Protein-1 and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndromes , 2003, Circulation.

[17]  T. Imaizumi,et al.  Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. , 2007, Journal of the American College of Cardiology.

[18]  E. Appella,et al.  Human monocyte chemoattractant protein‐1 (MCP‐1) Full‐length cDNA cloning, expression in mitogen‐stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE , 1989, FEBS letters.

[19]  Masatoshi Ishibashi,et al.  Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. , 2006, Journal of the American College of Cardiology.

[20]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[21]  B. Rollins,et al.  Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1–deficient Mice , 1998, The Journal of experimental medicine.

[22]  A. Tall,et al.  Interleukin 8 Is Induced by Cholesterol Loading of Macrophages and Expressed by Macrophage Foam Cells in Human Atheroma (*) , 1996, The Journal of Biological Chemistry.

[23]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[24]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[25]  P. Tipping,et al.  Interleukin-8 production by macrophages from atheromatous plaques. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[26]  H. Sinzinger,et al.  Radiolabelling autologous monocytes with 111-indium-oxine for reinjection in patients with atherosclerosis. , 1990, Progress in clinical and biological research.

[27]  B. Rollins,et al.  Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  E. Leonard,et al.  Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes. , 1990, Journal of immunology.

[29]  F. Blankenberg,et al.  Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats , 2001, Pediatric Radiology.

[30]  D. Graves,et al.  Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. , 1992, Journal of immunology.

[31]  T. Schall,et al.  Local expression of inflammatory cytokines in human atherosclerotic plaques. , 1994, Journal of atherosclerosis and thrombosis.

[32]  W D Wagner,et al.  A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1994, Circulation.

[33]  O. Quehenberger,et al.  Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[34]  K. Murao,et al.  Regulation of Expression of the Human Monocyte Chemotactic Protein-1 Receptor (hCCR2) by Cytokines* , 1997, The Journal of Biological Chemistry.

[35]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[36]  D H Blankenhorn,et al.  A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1992, Circulation.

[37]  H. Strauss,et al.  Detection of Monocyte Chemoattractant Protein-1 Receptor Expression in Experimental Atherosclerotic Lesions: An Autoradiographic Study , 2001, Circulation.

[38]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[39]  Leonard,et al.  Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. , 1990, The American journal of pathology.

[40]  W D Wagner,et al.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[41]  A. J. Valente,et al.  Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. , 1992, Circulation.

[42]  M. Daemen,et al.  Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. , 2004, The New England journal of medicine.

[43]  S. Coughlin,et al.  Monocyte chemoattractant protein-1 in human atheromatous plaques. , 1991, The Journal of clinical investigation.

[44]  K. Burnand,et al.  Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques. , 1999, The American journal of pathology.